Chronic myeloid leukaemia: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• ABL1 12
• TP53 1
• JAK 1
• AKT 0
• IDH 4
• ERK 0
• FLT3 2
• PI3K 0
• JNK 0
• STAT3 0
• BCL-2 2
• CD19 1
• HSP90 0
• KIT 1
• PDGFR 0
• CSF1R 2
• HDAC 0
• HIF-1 0
• IL-1 2
• MAPK 0
• PPAR 0
• AMPK 0
• CD123 0
• CD38 1
• CTNNB1 0
• EGFR 0
• FGFR 0
• mTOR 0
• NLRP3 0
• NRF2 0
• RAS 0
• RUNX1 0
• BTK 0
• CD20 0
• CD22 0
• CD33 0
• CD40 0
• CD47 1
• CTLA-4 0
• CXCR4 0
• G6PD 0
• GLP-1 0
• IL-15 0
• IL-6 1
• KRAS 0
• MEK 1
• MYC 0
• NPM1 0
• NRAS 0
• PD-1 0
• PRMT5 0
• PTEN 0
• SGLT2 0
• SIRT1 0
• TIM-3 0
• YAP 0

24 of 475 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R01

  The Role of Cell Competition in Shaping the Clonal Structure of Hematopoiesis

  Washington University· Saint Louis, United States· US$465,749 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · K99

  The Epitranscriptomic-Microtubule Axis as a Novel Mechanism of Ponatinib induced Cardiotoxicity

  University of Illinois at Chicago· Chicago, United States· US$139,113 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R21

  Interferon-γ in combination with donor leukocyte infusion to treat relapsed acute myeloid leukemia and myelodysplastic syndromes after haploidentical donor stem cell transplantation

  University of Pittsburgh at Pittsburgh· Pittsburgh, United States· US$408,829 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · F31

  Role of ABL kinases in regulating DNA damage repair and transcription-replication conflicts in SCLC tumors

  Duke University· Durham, United States· US$43,742 awarded in fiscal year 2026· until Aug 2029

• NIH NCI · F30

  From Resistance to Innovation: Towards Countering Asciminib Resistance and Designing Next-Generation Allosteric Inhibitors against CML

  State University New York Stony Brook· Stony Brook, United States· US$42,647 awarded in fiscal year 2026· until Aug 2030

• European Commission (Horizon 2020) · ERC-STG

  Functional Interrogation of Non-coding DNA Sequences in leukemia development and drug resistance (FIND-seq)

  St. Anna Kinderkrebsforschung Gmbh· Wien, Austria· EU contribution €1,784,000· until Aug 2027

  The disease is named only in the funder's project summary, not in the title.

6 of 51 running projects, newest first. Listed amounts together: US$33.5m + €1.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

  NCT02530034· M.D. Anderson Cancer Center· Updated 4 Nov 2026

  “FDA Clinical Hold”Registry text, quoted unchanged. Source

• Suspended

  Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

  NCT06630221· Abhay Singh, MD MPH· Updated 9 Oct 2026

  “Funding unavailable”Registry text, quoted unchanged. Source

• Withdrawn

  A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

  NCT06597734· M.D. Anderson Cancer Center· Updated 5 Oct 2026

  “PI request”Registry text, quoted unchanged. Source

• Suspended

  Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.

  NCT06071624· Huda Salman· Updated 24 Sept 2026

  “Trial being transferred to new lead site”Registry text, quoted unchanged. Source

• Suspended

  ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

  NCT06680661· Leland Metheny· Updated 10 Sept 2026

  “insufficient funding”Registry text, quoted unchanged. Source

• Suspended

  Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

  NCT05400122· David Wald· Updated 14 Jul 2026

  “Drugs unavailable”Registry text, quoted unchanged. Source

• Terminated

  Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  NCT04550442· M.D. Anderson Cancer Center· Updated 5 Jun 2026

  “\<75% participation”Registry text, quoted unchanged. Source

• Terminated

  Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

  NCT05413915· Sarit Assouline· Updated 29 May 2026

  “Insufficient patient accrual”Registry text, quoted unchanged. Source

• Terminated

  Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

  NCT01962636· Masonic Cancer Center, University of Minnesota· Updated 20 May 2026

  “No longer a research question to answer.”Registry text, quoted unchanged. Source

• Terminated

  Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

  NCT03246906· Fred Hutchinson Cancer Center· Updated 14 May 2026

  “Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and Data Safety Monitoring Board recommendations.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

  NCT04802161· National Cancer Institute (NCI)· Source

• Allogeneic iNKT Cell Therapy (agenT-797) After SCT

  NCT07758218· University of Wisconsin, Madison· Source

• Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

  NCT07354074· Novartis Pharmaceuticals· Source

• Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

  NCT04925479· Novartis Pharmaceuticals· Source

• Asciminib Roll-over Study

  NCT04877522· Novartis Pharmaceuticals· Source

• A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

  2026-525234-39-00· Janssen Cilag International· Source

• A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

  NCT06788509· Janssen Research & Development, LLC· Source

• Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

  NCT06904066· National Cancer Institute (NCI)· Source

• Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

  NCT01742299· Novartis Pharmaceuticals· Source

• Cord Blood Transplant in Adults With Blood Cancers

  NCT05884333· Memorial Sloan Kettering Cancer Center· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 4
• Mendelian Randomization Analysis 3
• CRISPR-Cas Systems 2
• Gene Expression Profiling 6
• Sequence Analysis, RNA 2
• Exome Sequencing 1
• Proteomics 5
• Metabolomics 3
• Mass Spectrometry 2
• Flow Cytometry 13
• Xenograft Model Antitumor Assays 19
• Magnetic Resonance Imaging 4
• Machine Learning 3
• Cohort Studies 9
• Genome-Wide Association Study 3

• Programmable and selective silencing of oncogenic fusion transcripts by CRISPR-Cas13b via breakpoint sequence recognition.

  Sci Adv, Oct 2026

• Targeting STAT5A via CRISPR/Cas9 restores TKI sensitivity in resistant chronic myeloid leukemia cells.

  Med Oncol, Apr 2026

See which targets of this disease your abstract mentions, and go to the people working on them.